2 results
Approved WMORecruiting
The primary objective of this study is to assess the efficacy of Triumeq versus placebo on overall survival, defined as death from any cause, in participants with ALS at 24 months or after a minimum of 212 events.
Approved WMORecruiting
Our study aim is to assess whether it is feasible to remove small breast cancers completely using VAB under US guidance.